selinexor + polatuzumab vedotin + bendamustine + rituximab

**selinexor + polatuzumab vedotin + bendamustine + rituximab** is an investigational combination regimen for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), especially in patients ineligible for transplantation or CAR T-cell therapy[5][1]. - **Selinexor** is a small molecule selective inhibitor of nuclear export (SINE) targeting exportin 1 (XPO1), leading to nuclear retention and activation of tumor suppressor proteins[3][5]. - **Polatuzumab vedotin** is an antibody-drug conjugate (ADC) targeting CD79b, a component of the B-cell receptor, delivering monomethyl auristatin E to induce cell death in malignant B cells[1][5]. - **Bendamustine** is an alkylating agent that induces cell death by causing DNA damage, used primarily in lymphoid malignancies[2][5]. - **Rituximab** is a monoclonal antibody targeting CD20 on B cells, leading to their depletion via multiple immune mechanisms[2][5]. The combination is currently being evaluated in a phase 1/2 clinical trial as a multi-agent therapy, with the goal of improving outcomes in patients who have failed prior treatments[5].

Brand names

Polivy (polatuzumab vedotin)Rituxan (rituximab)Treanda (bendamustine)None for selinexor, marketed as Xpovio (but usually referred to as generic selinexor)

Other names

S-PBR (used in clinical trial context for selinexor + polatuzumab vedotin + bendamustine + rituximab)selinexor + polatuzumab vedotin + bendamustine + rituximab